Semaglutide and Cardiovascular Risk: What a 2026 Meta-Analysis Shows
Episode Summary
A 2026 meta-analysis found 32% lower odds of major cardiovascular events with semaglutide, reinforcing cardiovascular benefit while emphasizing baseline risk, evidence limits, and indication-specific interpretation.